Functional non-nucleoside adenylyl cyclase inhibitors

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Bioconjugation Chemistry

Background:

• Adenylyl cyclase (AC) enzymes play crucial roles in cellular signaling.
• Developing targeted inhibitors with efficient intracellular delivery remains a challenge.
• Non-nucleoside inhibitors offer a versatile scaffold for drug development.

Purpose of the Study:

• To synthesize novel functional non-nucleoside adenylyl cyclase inhibitors.
• To create a modular system for conjugating inhibitors with biomolecules like tumor-targeting structures.
• To enable efficient intracellular delivery of inhibitors through cleavable linkages.

Main Methods:

• Chemical synthesis of novel non-nucleoside adenylyl cyclase inhibitors.
• Design and incorporation of cleavable linkers (reductive and acid-labile).
• Bioconjugation of inhibitors with thiol-containing biomolecules, including a cell-penetrating peptide.
• Live-cell Förster resonance energy transfer (FRET)-based assay to assess inhibitory activity.

Main Results:

• Successful synthesis of novel functional non-nucleoside adenylyl cyclase inhibitors.
• Demonstration of facile modification with thiol-containing biomolecules.
• Confirmation of efficient intracellular delivery via cleavable bonds in reductive and acidic environments.
• Successful bioconjugation of a poorly cell-permeable inhibitor with a cell-penetrating peptide.
• Significant adenylyl cyclase inhibition observed in live-cell FRET assays.

Conclusions:

• The developed synthetic strategy allows for the creation of targeted adenylyl cyclase inhibitors.
• Cleavable linkers ensure efficient intracellular drug release in relevant cellular compartments.
• The bioconjugation approach enhances the delivery of otherwise poorly cell-permeable inhibitors.
• These novel inhibitors show potent activity in a cellular context, highlighting their therapeutic potential.